Maedeh Yousefi Roozbahani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maedeh Yousefi Roozbahani has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Aziz Eghbali
Clinical Research Development Center of Aliasghar Hospital, Iran University of Medical Sciences, Tehran, Iran
1 shared publication Khatereh Tavajohi
Aliasghar Children Hospital Tehran Iran
1 shared publication- Seyed Mehrab Safdari
Departments of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Soudabeh Hosseini
Departments of Hematology and Blood Transfusion, School of Allied Medicine Iran University of Medical Sciences Tehran Iran
1 shared publication
Latest Publications
- Open Access
- 17 November 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (11) , e9583
Fanconi Anemia: Challenges in Diagnosis and Management—A Case Series Report
Fanconi anemia (FA) is a rare inherited disorder characterized by congenital abnormalities, progressive bone marrow failure, and a predisposition to malignancies. Detecting FA can be challenging, as it involves identifying increased chromosomal sensitivity to DNA cross‐linking agents and detecting causative genetic variants via genome sequencing. We report two cases of siblings with FA, both confirmed to have the FANCD2 variant through whole‐exome sequencing (WES). The first patient presented with epistaxis, petechiae, ecchymosis, and lower limb edema. The second patient exhibited epistaxis, diabetes, developmental delay, and physical abnormalities. Interestingly, both patients had negative results on the initial chromosomal breakage test with mitomycin C, a commonly used diagnostic tool for FA. However, further investigation with WES revealed the presence of the FANCD2 variant, confirming the FA diagnosis. This case report highlights the challenges in diagnosing FA, particularly when initial screening tests yield negative results. Molecular genetic testing, such as WES, can provide a definitive diagnosis and guide appropriate management strategies. Early and accurate diagnosis is crucial for improving outcomes in individuals with this potentially fatal illness, as promising advancements in treatments such as hematopoietic stem cell transplantation and gene therapy offer hope for addressing FA.
- 17 November 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (11) , e9583
Open AccessFanconi Anemia: Challenges in Diagnosis and Management—A Case Series Report
Fanconi anemia (FA) is a rare inherited disorder characterized by congenital abnormalities, progressive bone marrow failure, and a predisposition to malignancies. Detecting FA can be challenging, as it involves identifying increased chromosomal sensitivity to DNA cross‐linking agents and detecting causative genetic variants via genome sequencing. We report two cases of siblings with FA, both confirmed to have the FANCD2 variant through whole‐exome sequencing (WES). The first patient presented with epistaxis, petechiae, ecchymosis, and lower limb edema. The second patient exhibited epistaxis, diabetes, developmental delay, and physical abnormalities. Interestingly, both patients had negative results on the initial chromosomal breakage test with mitomycin C, a commonly used diagnostic tool for FA. However, further investigation with WES revealed the presence of the FANCD2 variant, confirming the FA diagnosis. This case report highlights the challenges in diagnosing FA, particularly when initial screening tests yield negative results. Molecular genetic testing, such as WES, can provide a definitive diagnosis and guide appropriate management strategies. Early and accurate diagnosis is crucial for improving outcomes in individuals with this potentially fatal illness, as promising advancements in treatments such as hematopoietic stem cell transplantation and gene therapy offer hope for addressing FA.